Early over-expression of GRP receptors in prostatic carcinogenesis

Prostate

Volumn 74, Issue 2, 2014, Pages 217-224

  Körner, Meike ^a   Waser, Beatrice ^a   Rehmann, Ruth ^a   Reubi, Jean Claude ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

bombesin receptor; GRP receptor; in vitro receptor autoradiography; prostate cancer; prostatic intraepithelial neoplasia

Indexed keywords

BOMBESIN[4 TYROSINE]; BOMBESIN[IODINE 125]; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; RADIOACTIVE MATERIAL; UNCLASSIFIED DRUG;

ARTICLE; AUTORADIOGRAPHY; CANCER INCIDENCE; DRUG BINDING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; OPTICAL DENSITY; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR DENSITY; STAINING;

BOMBESIN RECEPTOR; GRP RECEPTOR; IN VITRO RECEPTOR AUTORADIOGRAPHY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA;

ADENOCARCINOMA; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; AUTORADIOGRAPHY; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IODINE RADIOISOTOPES; MALE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, BOMBESIN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84891155877     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22743     Document Type: Article

References (35)

1. Reubi JC,. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003; 24: 389-427.
2. Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP,. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010; 139: 742-753.
3. Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, Vitek P, Sundin A, Plöckinger U,. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology 2009; 90: 184-189.
4. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ,. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-518.
5. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP,. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA0, Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130.
6. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, Mäcke HR, Rochlitz C, Müller-Brand J, Walter MA,. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011; 29: 2416-2423.
7. Jensen RT, Battey JF, Spindel ER, Benya RV,. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: Nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev 2008; 60: 1-42.
8. Markwalder R, Reubi JC,. Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation. Cancer Res 1999; 59: 1152-1159.
9. Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M,. Bombesin receptor subtypes in human cancers: Detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin (6-14). Clin Cancer Res 2002; 8: 1139-1146.
10. Sharif TR, Luo W, Sharif M,. Functional expression of bombesin receptor in most adult and pediatric human glioblastoma cell lines; role in mitogenesis and in stimulating the mitogen-activated protein kinase pathway. Mol Cell Endocrinol 1997; 130: 119-130.
11. Reubi JC, Körner M, Waser B, Mazzucchelli L, Guillou L,. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging 2004; 31: 803-810.
12. Moody TW, Chan D, Fahrenkrug J, Jensen RT,. Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Des 2003; 9: 495-509.
13. Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR,. Radiopeptide imaging and therapy in Europe. J Nucl Med 2011; 52: 42S-55S.
14. De Vincentis G, Remediani S, Varvarigou AD, Di Santo G, Iori F, Laurenti C, Scopinaro F,. Role of 99mTc-bombesin scan in diagnosis and staging of prostate cancer. Cancer Biother Radiopharm 2004; 19: 81-84.
15. Van de Wiele C, Phonteyne P, Pauwels P, Goethals I, Van den Broecke R, Cocquyt V, Dierckx RA,. Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. J Nucl Med 2008; 49: 260-264.
16. Gornik G, Mansi R, Abiraj K, Knippen S, Grosu A, Maecke H, Weber W,. Evaluation of the GRPR radioantagonist Cu-64-CB-TE2A-AR-06 in mice and men. J Nucl Med 2011; 52: 22.
17. 3) and F-18 FDG PET in patients with recurrent gliomas and comparison to grading: Preliminary results. Clin Nucl Med 2011; 36: 101-108.
18. Lantry LE, Cappelletti E, Maddalena ME, Fox JS, Feng W, Chen J, Thomas R, Eaton SM, Bogdan NJ, Arunachalam T, Reubi JC, Raju N, Metcalfe EC, Lattuada L, Linder KE, Swenson RE, Tweedle MF, Nunn AD,. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 2006; 47: 1144-1152.
19. Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC, Maecke HR,. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007; 34: 1198-1208.
20. Johnson CV, Shelton T, Smith CJ, Ma L, Perry MC, Volkert WA, Hoffman TJ,. Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biother Radiopharm 2006; 21: 155-166.
21. 177Lu-AMBA Bombesin analogue in hormone refractory prostate cancer patients: A phase I escalation study with single-cycle administrations. Eur J Nucl Med Mol Imaging 2007; 34: S221.
22. Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, Reubi JC,. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008; 49: 318-326.
23. Mansi R, Wang X, Forrer F, Kneifel S, Tamma ML, Waser B, Cescato R, Reubi JC, Maecke HR,. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10- tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 2009; 15: 5240-5249.
24. Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, Borkowski S, Reubi JC, Maecke HR,. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 2011; 38: 97-107.
25. Epstein JI,. Precursor lesions to prostatic adenocarcinoma. Virchows Arch 2009; 454 (1): 1-16.
26. Bostwick DG, Cheng L,. Precursors of prostate cancer. Histopathology 2012; 60: 4-27.
27. Körner M, Waser B, Schonbrunn A, Perren A, Reubi JC,. Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo Somatostatin receptor targeting. Am J Surg Pathol 2012; 36: 242-252.
28. Körner M, Waser B, Thalmann GN, Reubi JC,. High expression of NPY receptors in the human testis. Mol Cell Endocrinol 2011; 337: 62-70.
29. Häussler O, Epstein JI, Amin MB, Heitz PU, Hailemariam S,. Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer. Hum Pathol 1999; 30: 1077-1086.
30. Helpap B,. Cell kinetic studies on prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia (AAH) of the prostate. Pathol Res Pract 1995; 191: 904-907.
31. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M,. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 1989; 63: 1714-1720.
32. Xiao D, Qu X, Weber HC,. GRP receptor-mediated immediate early gene expression and transcription factor Elk-1 activation in prostate cancer cells. Regul Pept 2002; 109: 141-148.
33. Rick FG, Abi-Chaker Am, Szalontay L, Perez R, Jaszberenyi M, Jayakumar AR, Shamaladevi N, Szepeshazi K, Vidaurre I, Halmos G, Krishan A, Block NL, Schally AV,. Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist. Proc Natl Acad Sci USA 2013; 110: 2617-2622.
34. Plonowski A, Nagy A, Schally AV, Sun B, Groot K, Halmos G,. In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215. Int J Cancer 2000; 88: 652-657.
35. Stangelberger A, Schally AV, Varga JL, Zarandi M, Szepeshazi K, Armatis P, Halmos G,. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. Clin Cancer Res 2005; 11: 49-57.